Abstract
Background: Despite the successful introduction of combined antiretroviral therapy, the prevalence of mild to moderate forms of HIV-associated neurocognitive disorders (HAND) remains high. It has been demonstrated that neuronal injury caused by HIV is excitotoxic and inflammatory, and it correlates with neurocognitive decline in HAND. Endocannabinoid system (ECS) protects the body from excitotoxicity and neuroinflammation on demand and presents a promising therapeutic target for treating HAND. Here, we firstly discuss the potential pathogenesis of HAND. We secondly discuss the structural and functional changes in the ECS that are currently known among HAND patients. We thirdly discuss current clinical and preclinical findings concerning the neuroprotective and anti-inflammatory properties of the ECS among HAND patients. Fourth, we will discuss the interactions between the ECS and neuroendocrine systems, including the hypothalamic-pituitary-adrenocortical (HPA) and hypothalamic-pituitary-gonadal (HPG) axes under the HAND conditions.
Materials and Methods: We have carried out a review of the literature using PubMed to summarize the current state of knowledge on the association between ECS and HAND.
Results: The ECS may be ideally suited for modulation of HAND pathophysiology. Direct activation of presynaptic cannabinoid receptor 1 or reduction of cannabinoid metabolism attenuates HAND excitotoxicity. Chronic neuroinflammation associated with HAND can be reduced by activating cannabinoid receptor 2 on immune cells. The sensitivity of the ECS to HIV may be enhanced by increased cannabinoid receptor expression in HAND. In addition, indirect regulation of the ECS through modulation of hormone-related receptors may be a potential strategy to influence the ECS and also alleviate the progression of HAND due to the reciprocal inhibition of the ECS by the HPA and HPG axes.
Conclusions: Taken together, targeting the ECS may be a promising strategy to alleviate the inflammation and neurodegeneration caused by HIV-1 infection. Further studies are required to clarify the role of endocannabinoid signaling in HIV neurotoxicity. Strategies promoting endocannabinoid signaling may slow down cognitive decline of HAND are proposed.
Keywords: 2-arachidonoylglycerol, HIV-associated neurocognitive disorders, N-arachidonylethanolamine, cannabinoid receptors, endocannabinoid system
Similar articles
-
Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder.Brain Res. 2019 Dec 1;1724:146467. doi: 10.1016/j.brainres.2019.146467. Epub 2019 Sep 17.PMID: 31539547 Free PMC article. Review.
-
Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.IBRO Neurosci Rep. 2021 Jan 25;10:109-118. doi: 10.1016/j.ibneur.2021.01.004. eCollection 2021 Jun.PMID: 34179865 Free PMC article.
-
Endocannabinoid system: Role in blood cell development, neuroimmune interactions and associated disorders.J Neuroimmunol. 2021 Apr 15;353:577501. doi: 10.1016/j.jneuroim.2021.577501. Epub 2021 Jan 28.PMID: 33571815 Review.
-
The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders.Hum Reprod Update. 2020 Jun 18;26(4):586-602. doi: 10.1093/humupd/dmaa005.PMID: 32347309 Free PMC article. Review.
-
Alterations in Brain Cannabinoid Receptor Levels Are Associated with HIV-Associated Neurocognitive Disorders in the ART Era: Implications for Therapeutic Strategies Targeting the Endocannabinoid System.Viruses. 2021 Aug 31;13(9):1742. doi: 10.3390/v13091742.PMID: 34578323 Free PMC article.